Vitamin e facilitates the inactivation of the kinase akt by the phosphatase PHLPP1

Science Signaling

Volumn 6, Issue 267, 2013, Pages

  Huang, Po Hsien ^a,b   Chuang, Hsiao Ching ^a   Chou, Chih Chien ^a   Wang, Huiling ^a,c   Lee, Su Lin ^a   Yang, Hsiao Ching ^d   Chiu, Hao Chieh ^a,e   Kapuriya, Naval ^a,f   Wang, Dasheng ^a   Kulp, Samuel K ^a   Chen, Ching Shih ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^d FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^f Shree M and N Virani Science College   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ALPHA VE5; BETA VE5; GAMMA TOCOPHEROL; LIGAND; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PH DOMAIN LEUCINE RICH REPEAT PROTEIN PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE; PLECKSTRIN; PROTEIN KINASE B; TOCOPHEROL DERIVATIVE; UNCLASSIFIED DRUG; ENZYME INHIBITOR; NUCLEAR PROTEIN; PHLPP1 PROTEIN, HUMAN; SERINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CELL MEMBRANE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; ENZYME INACTIVATION; HYDROGEN BOND; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROSTATE CANCER; PROTEIN DEPHOSPHORYLATION; PROTEIN INTERACTION; PROTEIN STRUCTURE; SEQUENCE HOMOLOGY; SITE DIRECTED MUTAGENESIS; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CONFOCAL MICROSCOPY; DRUG EFFECT; DRUG SCREENING; GENETICS; HUMAN; METABOLISM; NUDE MOUSE; PHOSPHORYLATION; PROTEIN BINDING; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ALPHA-TOCOPHEROL; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MEMBRANE; ENZYME INHIBITORS; GAMMA-TOCOPHEROL; HUMANS; MALE; MICE; MICE, NUDE; MICROSCOPY, CONFOCAL; NUCLEAR PROTEINS; PHOSPHOPROTEIN PHOSPHATASES; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; SERINE; SIGNAL TRANSDUCTION; VITAMIN E; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875716808     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2003816     Document Type: Article

References (40)

1. S. M. Lippman, E. A. Klein, P. J. Goodman, M. S. Lucia, I. M. Thompson, L. G. Ford, H. L. Parnes, L. M. Minasian, J. M. Gaziano, J. A. Hartline, J. K. Parsons, J. D. Bearden III, E. D. Crawford, G. E. Goodman, J. Claudio, E. Winquist, E. D. Cook, D. D. Karp, P. Walther, M. M. Lieber, A. R. Kristal, A. K. Darke, K. B. Arnold, P. A. Ganz, R. M. Santella, D. Albanes, P. R. Taylor, J. L. Probstfield, T. J. Jagpal, J. J. Crowley, F. L. Meyskens Jr., L. H. Baker, C. A. Coltman Jr., Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 301, 39-51 (2009).
2. J. Ju, S. C. Picinich, Z. Yang, Y. Zhao, N. Suh, A. N. Kong, C. S. Yang, Cancer-preventive activities of tocopherols and tocotrienols. Carcinogenesis 31, 533-542 (2010).
3. R. Gysin, A. Azzi, T. Visarius, g-Tocopherol inhibits human cancer cell cycle progression and cell proliferation by down-regulation of cyclins. FASEB J. 16, 1952-1954 (2002).
4. R. V. Cooney, A. A. Franke, P. J. Harwood, V. Hatch-Pigott, L. J. Custer, L. J. Mordan, g-Tocopherol detoxification of nitrogen dioxide: Superiority to a-tocopherol. Proc. Natl. Acad. Sci. U.S.A. 90, 1771-1775 (1993).
5. R. Brigelius-Flohé, Vitamin E: The shrew waiting to be tamed. Free Radic. Biol. Med. 46, 543-554 (2009).
6. P. Kempná, E. Reiter, M. Arock, A. Azzi, J. M. Zingg, Inhibition of HMC-1 mast cell proliferation by vitamin E: Involvement of the protein kinase B pathway. J. Biol. Chem. 279, 50700-50709 (2004).
7. H. J. Lee, J. Ju, S. Paul, J. Y. So, A. DeCastro, A. Smolarek, M. J. Lee, C. S. Yang, H. L. Newmark, N. Suh, Mixed tocopherols prevent mammary tumorigenesis by inhibiting estrogen action and activating PPAR-g. Clin. Cancer Res. 15, 4242-4249 (2009).
8. M. Chen, C. P. Pratt, M. E. Zeeman, N. Schultz, B. S. Taylor, A. O'Neill, M. Castillo-Martin, D. G. Nowak, A. Naguib, D. M. Grace, J. Murn, N. Navin, G. S. Atwal, C. Sander, W. L. Gerald, C. Cordon-Cardo, A. C. Newton, B. S. Carver, L. C. Trotman, Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTENmutant prostate cancer progression. Cancer Cell 20, 173-186 (2011).
9. L. C. Cantley, The phosphoinositide 3-kinase pathway. Science 296, 1655-1657 (2002).
10. I. Vivanco, C. L. Sawyers, The phosphatidylinositol 3-kinase-AKT pathway in human cancer. Nat. Rev. Cancer 2, 489-501 (2002).
11. R. C. Hresko, M. Mueckler, mTOR·RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J. Biol. Chem. 280, 40406-40416 (2005).
12. D. D. Sarbassov, D. A. Guertin, S. M. Ali, D. M. Sabatini, Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101 (2005).
13. J. R. Bayascas, D. R. Alessi, Regulation of Akt/PKB Ser473 phosphorylation. Mol. Cell 18, 143-145 (2005).
14. T. Gao, F. Furnari, A. C. Newton, PHLPP: A phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol. Cell 18, 13-24 (2005).
15. J. Brognard, E. Sierecki, T. Gao, A. C. Newton, PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol. Cell 25, 917-931 (2007).
16. M. C. Mendoza, J. Blenis, PHLPPing it off: Phosphatases get in the Akt. Mol. Cell 25, 798-800 (2007).
17. L. Zhuang, J. Lin, M. L. Lu, K. R. Solomon, M. R. Freeman, Cholesterol-rich lipid rafts mediate Akt-regulated survival in prostate cancer cells. Cancer Res. 62, 2227-2231 (2002).
18. L. Zhuang, J. Kim, R. M. Adam, K. R. Solomon, M. R. Freeman, Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J. Clin. Invest. 115, 959-968 (2005).
19. R. Lasserre, X. J. Guo, F. Conchonaud, Y. Hamon, O. Hawchar, A. M. Bernard, S. M. Soudja, P. F. Lenne, H. Rigneault, D. Olive, G. Bismuth, J. A. Nunès, B. Payrastre, D. Marguet, H. T. He, Raft nanodomains contribute to Akt/PKB plasma membrane recruitment and activation. Nat. Chem. Biol. 4, 538-547 (2008).
20. X. Gao, P. R. Lowry, X. Zhou, C. Depry, Z. Wei, G. W. Wong, J. Zhang, PI3K/Akt signaling requires spatial compartmentalization in plasma membrane microdomains. Proc. Natl. Acad. Sci. U.S.A. 108, 14509-14514 (2011).
21. J. Atkinson, T. Harroun, S. R. Wassall, W. Stillwell, J. Katsaras, The location and behavior of a-tocopherol in membranes. Mol. Nutr. Food Res. 54, 641-651 (2010).
22. S. Lemaire-Ewing, C. Desrumaux, D. Néel, L. Lagrost, Vitamin E transport, membrane incorporation and cell metabolism: Is a-tocopherol in lipid rafts an oar in the lifeboat? Mol. Nutr. Food Res. 54, 631-640 (2010).
23. R. M. Adam, N. K.Mukhopadhyay, J. Kim,D. Di Vizio, B. Cinar, K. Boucher, K. R. Solomon, M. R. Freeman, Cholesterol sensitivity of endogenous and myristoylated Akt. Cancer Res. 67, 6238-6246 (2007).
24. M. C. Royer, S. Lemaire-Ewing, C. Desrumaux, S. Monier, J. P. Pais de Barros, A. Athias, D. Néel, L. Lagrost, 7-Ketocholesterol incorporation into sphingolipid/cholesterolenriched (lipid raft) domains is impaired by vitamin E: A specific role for a-tocopherol with consequences on cell death. J. Biol. Chem. 284, 15826-15834 (2009).
25. G. Hannigan, A. A. Troussard, S. Dedhar, Integrin-linked kinase: A cancer therapeutic target unique among its ILK. Nat. Rev. Cancer 5, 51-63 (2005).
26. B. Ananthanarayanan, Q. Ni, J. Zhang, Signal propagation from membrane messengers to nuclear effectors revealed by reporters of phosphoinositide dynamics and Akt activity. Proc. Natl. Acad. Sci. U.S.A. 102, 15081-15086 (2005).
27. C. C. Thomas, M. Deak, D. R. Alessi, D. M. van Aalten, High-resolution structure of the pleckstrin homology domain of protein kinase B/Akt bound to phosphatidylinositol (3,4,5)-trisphosphate. Curr. Biol. 12, 1256-1262 (2002).
28. C. C. Milburn, M. Deak, S. M. Kelly, N. C. Price, D. R. Alessi, D. M. Van Aalten, Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change. Biochem. J. 375, 531-538 (2003).
29. B. S. Carver, C. Chapinski, J. Wongvipat, H. Hieronymus, Y. Chen, S. Chandarlapaty, V. K. Arora, C. Le, J. Koutcher, H. Scher, P. T. Scardino, N. Rosen, C. L. Sawyers, Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTENdeficient prostate cancer. Cancer Cell 19, 575-586 (2011).
30. D. J. Mulholland, L. M. Tran, Y. Li, H. Cai, A. Morim, S. Wang, S. Plaisier, I. P. Garraway, J. Huang, T. G. Graeber, H. Wu, Cell autonomous role of PTEN in regulating castrationresistant prostate cancer growth. Cancer Cell 19, 792-804 (2011).
31. P. Patrignani, M. R. Panara, S. Tacconelli, F. Seta, T. Bucciarelli, G. Ciabattoni, P. Alessandrini, A. Mezzetti, G. Santini, M. G. Sciulli, F. Cipollone, G. Davì, P. Gallina, G. B. Bon, C. Patrono, Effects of vitamin E supplementation on F2-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. Circulation 102, 539-545 (2000).
32. X. Li, H. Yang, J. Liu, M. D. Schmidt, T. Gao, Scribble-mediated membrane targeting of PHLPP1 is required for its negative regulation of Akt. EMBO Rep. 12, 818-824 (2011).
33. H. B. Pearson, P. A. Perez-Mancera, L. E. Dow, A. Ryan, P. Tennstedt, D. Bogani, I. Elsum, A. Greenfield, D. A. Tuveson, R. Simon, P. O. Humbert, SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia. J. Clin. Invest. 121, 4257-4267 (2011).
34. C. Nitsche, M. Edderkaoui, R. M. Moore, G. Eibl, N. Kasahara, J. Treger, P. J. Grippo, J. Mayerle, M. M. Lerch, A. S. Gukovskaya, The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation. Gastroenterology 142, 377-387.e5 (2012).
35. S. F. Barnett, D. Defeo-Jones, S. Fu, P. J. Hancock, K. M. Haskell, R. E. Jones, J. A. Kahana, A. M. Kral, K. Leander, L. L. Lee, J. Malinowski, E. M. McAvoy, D. D. Nahas, R. G. Robinson, H. E. Huber, Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem. J. 385, 399-408 (2005).
36. D. Mahadevan, G. Powis, E. A. Mash, B. George, V. M. Gokhale, S. Zhang, K. Shakalya, L. Du-Cuny, M. Berggren, M. A. Ali, U. Jana, N. Ihle, S. Moses, C. Franklin, S. Narayan, N. Shirahatti, E. J. Meuillet, Discovery of a novel class of AKT pleckstrin homology domain inhibitors. Mol. Cancer Ther. 7, 2621-2632 (2008).
37. S. A. Moses, M. A. Ali, S. Zuohe, L. Du-Cuny, L. L. Zhou, R. Lemos, N. Ihle, A. G. Skillman, S. Zhang, E. A. Mash, G. Powis, E. J. Meuillet, In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT. Cancer Res. 69, 5073-5081 (2009).
38. L. Salmena, A. Carracedo, P. P. Pandolfi, Tenets of PTEN tumor suppression. Cell 133, 403-414 (2008).
39. C. S. Chen, S. C. Weng, P. H. Tseng, H. P. Lin, C. S. Chen, Histone acetylationindependent effect of histone deacetylase inhibitors on Akt through the reshuffling of protein phosphatase 1 complexes. J. Biol. Chem. 280, 38879-38887 (2005).
40. W. Kabsch, C. Sander, Dictionary of protein secondary structure: Pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 22, 2577-2637 (1983).